Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,898.00-1.58%ETH$2,405.51-3.20%GOLD$4,390.60+1.33%OIL$103.24-2.45%
Smart Investors Daily
FB

NASDAQ · FBLG

FibroBiologics, Inc. Common Stock

Healthcare · Biotechnology

$1.44

Down-$0.11 (-7.10%)

Updated Sep 16, 2026, 6:59 AM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.4M
P/E ratio
-1
Dividend yield
0.00%
52-week range
$0.24 – $5.40
Volume
177.21K
Avg. volume
1.39M

Price performance

FBLG price history

1M range · 20 trading sessions · Daily adjusted prices

FBLG closed at $1.44 after 20 trading sessions, up 26.32% for the selected period.

Last close
$1.44
Period change
+26.32%
Period low
$1.14
Period high
$2.11
Daily close
View OHLC price history
FBLG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.55$1.575$1.44$1.44177.21K
Sep 14, 2026$1.60$1.6899$1.5206$1.55174.5K
Sep 11, 2026$1.70$1.7357$1.61$1.61107.29K
Sep 10, 2026$1.73$1.7963$1.6713$1.7383.79K
Sep 9, 2026$1.73$1.80$1.62$1.76138.31K
Sep 8, 2026$1.80$1.8155$1.619$1.71166.41K
Sep 4, 2026$1.73$1.90$1.71$1.81210.46K
Sep 3, 2026$1.80$1.9005$1.70$1.76366K
Sep 2, 2026$2.17$2.175$1.8649$1.95639.03K
Sep 1, 2026$1.73$2.1999$1.72$2.111.55M
Aug 31, 2026$1.46$1.7899$1.401$1.72508.1K
Aug 28, 2026$1.50$1.54$1.41$1.44143.79K
Aug 27, 2026$1.44$1.52$1.42$1.49217.83K
Aug 26, 2026$1.39$1.4699$1.33$1.41164.69K
Aug 25, 2026$1.34$1.49$1.33$1.40191.3K
Aug 24, 2026$1.42$1.50$1.31$1.35252.94K
Aug 21, 2026$1.35$1.4888$1.34$1.44570.61K
Aug 20, 2026$1.22$1.37$1.20$1.29415.52K
Aug 19, 2026$1.17$1.28$1.14$1.19390.41K
Aug 18, 2026$1.09$1.18$1.01$1.14303.53K

Latest FBLG news

The latest Smart Investors Daily articles mentioning FBLG.

Stock researchCompany · Overview

FBLG research

Overview

Company profile and research snapshot.

Company profile

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
FBLG recent ratings
DateFirmRatingTarget
Aug 4, 2026HC Wainwright & Co.Buy—
May 4, 2026Maxim GroupHold—
Apr 16, 2026HC Wainwright & Co.Buy—
Mar 26, 2026D. Boral CapitalHold—
Mar 12, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.

Yahoo · Sep 3, 2026

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers

Yahoo · Sep 1, 2026

FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,716,055, titled "Treatment of Disc Degenerative Disease and Stimulation of Proteoglycan Synthesis by Fibr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By